REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based...
Arrowhead Research: Fiscal Q3 Earnings Snapshot
- Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET
- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company’s Board of Directors approved...
- Study completion anticipated in mid-2027
Deep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline in SHASTA-3 and SHASTA-4, respectively Statistically significant reduction in acute pancreatitis...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal...
REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition People living with FCS have extremely high triglyceride levels...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that...